Literature DB >> 17442845

Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Elizabeth A Reap1, Sergey A Dryga, John Morris, Bryan Rivers, Pamela K Norberg, Robert A Olmsted, Jeffrey D Chulay.   

Abstract

Development of vaccines against cytomegalovirus (CMV) is an important public health priority. We used a propagation-defective, single-cycle RNA replicon vector system derived from an attenuated strain of an alphavirus, Venezuelan equine encephalitis virus, to produce virus-like replicon particles (VRP) expressing various combinations of pp65, IE1, or gB proteins of human CMV. Protein expression in VRP-infected cells was highest with single-promoter replicons expressing pp65, IE1, a pp65/IE1 fusion protein, or the extracellular domain of gB and with double-promoter replicons expressing pp65 and IE1. Protein expression was lower with double- and triple-promoter replicons expressing gB, especially the full-length form of gB. BALB/c mice immunized with VRP expressing gB developed high titers of neutralizing antibody to CMV, and mice immunized with VRP expressing pp65, IE1, or a pp65/IE1 fusion protein developed robust antigen-specific T-cell responses as measured by gamma interferon enzyme-linked immunospot assay. Three overlapping immunodominant pp65 peptides contained a nine-amino-acid sequence (LGPISGHVL) that matches the consensus binding motif for a major histocompatibility complex H2-D(d) T-cell epitope. These data provide the basis for further development and clinical evaluation of an alphavirus replicon vaccine for CMV expressing the pp65, IE1, and gB proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442845      PMCID: PMC1951075          DOI: 10.1128/CVI.00037-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  45 in total

1.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.

Authors:  Z Gyulai; V Endresz; K Burian; S Pincus; J Toldy; W I Cox; C Meric; S Plotkin; E Gönczöl; K Berencsi
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

3.  Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis.

Authors:  G H MacDonald; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles.

Authors:  U B Balasuriya; H W Heidner; J F Hedges; J C Williams; N L Davis; R E Johnston; N J MacLachlan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses.

Authors:  S Schultz-Cherry; J K Dybing; N L Davis; C Williamson; D L Suarez; R Johnston; M L Perdue
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

6.  Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.

Authors:  P Pushko; M Bray; G V Ludwig; M Parker; A Schmaljohn; A Sanchez; P B Jahrling; J F Smith
Journal:  Vaccine       Date:  2000-08-15       Impact factor: 3.641

7.  Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).

Authors:  C S Morello; L D Cranmer; D H Spector
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

8.  Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection.

Authors:  N Bourne; M R Schleiss; F J Bravo; D I Bernstein
Journal:  J Infect Dis       Date:  2000-11-21       Impact factor: 5.226

9.  Epitopes involved in antibody-mediated protection from Ebola virus.

Authors:  J A Wilson; M Hevey; R Bakken; S Guest; M Bray; A L Schmaljohn; M K Hart
Journal:  Science       Date:  2000-03-03       Impact factor: 47.728

10.  Regulated expression of a Sindbis virus replicon by herpesvirus promoters.

Authors:  L Ivanova; S Schlesinger; P D Olivo
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more
  18 in total

1.  In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs.

Authors:  Kurt I Kamrud; V McNeil Coffield; Gary Owens; Christin Goodman; Kim Alterson; Max Custer; Michael A Murphy; Whitney Lewis; Sarah Timberlake; Elizabeth K Wansley; Peter Berglund; Jonathan Smith
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.

Authors:  Bolyn Hubby; Todd Talarico; Maureen Maughan; Elizabeth A Reap; Peter Berglund; Kurt I Kamrud; Laura Copp; Whitney Lewis; Chad Cecil; Pamela Norberg; Jordan Wagner; Aubrey Watson; Sarah Negri; Bruce K Burnett; Andrew Graham; Jonathan F Smith; Jeffrey D Chulay
Journal:  Vaccine       Date:  2007-10-05       Impact factor: 3.641

3.  Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.

Authors:  Elizabeth A Reap; John Morris; Sergey A Dryga; Maureen Maughan; Todd Talarico; Robert E Esch; Sarah Negri; Bruce Burnett; Andrew Graham; Robert A Olmsted; Jeffrey D Chulay
Journal:  Vaccine       Date:  2007-08-30       Impact factor: 3.641

4.  Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum.

Authors:  Daniel J Hackett; Changpin Zhang; Carla Stefanescu; Robert F Pass
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

5.  Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

Authors:  Yasushi Uematsu; Michael Vajdy; Ying Lian; Silvia Perri; Catherine E Greer; Harold S Legg; Grazia Galli; Giulietta Saletti; Gillis R Otten; Rino Rappuoli; Susan W Barnett; John M Polo
Journal:  Clin Vaccine Immunol       Date:  2012-05-23

6.  Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.

Authors:  Duane A Mitchell; Elias J Sayour; Elizabeth Reap; Robert Schmittling; Gabriel DeLeon; Pamela Norberg; Annick Desjardins; Allan H Friedman; Henry S Friedman; Gary Archer; John H Sampson
Journal:  Cancer Immunol Res       Date:  2014-11-11       Impact factor: 11.151

Review 7.  Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.

Authors:  Mark R Schleiss; Sallie R Permar; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

8.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

9.  Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells.

Authors:  Corinne Cayatte; Kirsten Schneider-Ohrum; Zhaoti Wang; Alivelu Irrinki; Nga Nguyen; Janine Lu; Christine Nelson; Esteban Servat; Lorraine Gemmell; Andrzej Citkowicz; Yi Liu; Gregory Hayes; Jennifer Woo; Gary Van Nest; Hong Jin; Gregory Duke; A Louise McCormick
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

Review 10.  Cytomegalovirus vaccine development.

Authors:  M R Schleiss
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.